{"id":2924,"date":"2018-09-30T14:55:07","date_gmt":"2018-09-30T14:55:07","guid":{"rendered":"https:\/\/lynxee.consulting\/?p=2924\/"},"modified":"2023-01-26T14:40:35","modified_gmt":"2023-01-26T14:40:35","slug":"europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors","status":"publish","type":"post","link":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/","title":{"rendered":"EUROPE &#8211; COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors"},"content":{"rendered":"<p style=\"text-align: justify\">The Commission notice of 24th September 2018 indicates that the new <b>EFSA\/ECHA guidance document on how to identify endocrine disruptors<\/b>, adopted and published in June 2018, will <b>apply<\/b> as of the date of application of <a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32018R0605&amp;from=FR\" target=\"_blank\" rel=\"noopener noreferrer\">Regulation (EU) No. 2018\/605<\/a>, <b>10th November 2018<\/b>, to address points 3.6.5 and 3.8.2 of Annex II of <a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32009R1107&amp;from=fr\" target=\"_blank\" rel=\"noopener noreferrer\">Regulation (EC) No. 1107\/2009<\/a>.<\/p>\n<p style=\"text-align: justify\">EFSA\/ECHA guidance document and the scientific criteria to identify endocrine disruptors, as defined in Regulation (EU) No. 2018\/605, will apply to on-going and future applications for approval or renewal of active substances, safeners or synergists.<\/p>\n<p>&nbsp;<\/p>\n<p><b>To download:<\/b><\/p>\n<p style=\"text-align: justify\"><a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:52018XC0924(02)&amp;from=EN\" target=\"_blank\" rel=\"noopener noreferrer\">Commission notice about the availability and applicability of a guidance document to implement Points 3.6.5 and 3.8.2 of Annex II of Regulation (EC) No 1107\/2009 of the European Parliament and of the Council as regards endocrine disrupting properties<\/a> (24\/09\/2018)<\/p>\n<p>&nbsp;<\/p>\n<p><b>See also our previous articles: <\/b><\/p>\n<p><a href=\"https:\/\/lynxee.consulting\/en\/europe-publication-of-the-guidance-document-efsaecha-on-identifying-endocrine-disruptors\/\" target=\"_blank\" rel=\"noopener noreferrer\">EUROPE: Publication of the guidance document EFSA\/ECHA on identifying endocrine disruptors<\/a><\/p>\n<p><a href=\"https:\/\/lynxee.consulting\/en\/europe-publication-of-endocrine-disruptors-criteria\/\" target=\"_blank\" rel=\"noopener noreferrer\">EUROPE: Publication of Endocrine disruptors criteria<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><b>Lynxee consulting<\/b>\u2019s team is at your disposal to answer your questions.<\/p>\n<p><b>Contact us!<\/b> <a href=\"https:\/\/lynxee.consulting\/en\/contact\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/lynxee.consulting\/en\/contact\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h6>Photo credit: crsssteve\/pixabay<\/h6>\n","protected":false},"excerpt":{"rendered":"<p>The Commission notice of 24th September 2018 indicates that the new EFSA\/ECHA guidance document on how to identify endocrine disruptors, adopted and published in June 2018,<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":7,"featured_media":2241,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[118],"class_list":["post-2924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulation","tag-endocrine-disruptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EUROPE - COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors - Lynxee consulting<\/title>\n<meta name=\"description\" content=\"The Commission notice of 24th September 2018 indicates that the new EFSA\/ECHA guidance document on how to identify endocrine disruptors, adopted and\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUROPE - COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors - Lynxee consulting\" \/>\n<meta property=\"og:description\" content=\"The Commission notice of 24th September 2018 indicates that the new EFSA\/ECHA guidance document on how to identify endocrine disruptors, adopted and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/\" \/>\n<meta property=\"og:site_name\" content=\"Lynxee consulting\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-30T14:55:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-26T14:40:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/06\/test-tubes-904546_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1441\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Adrien Margerit\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adrien Margerit\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/\",\"url\":\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/\",\"name\":\"EUROPE - COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors - Lynxee consulting\",\"isPartOf\":{\"@id\":\"https:\/\/lynxee.consulting\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/06\/test-tubes-904546_1920.jpg\",\"datePublished\":\"2018-09-30T14:55:07+00:00\",\"dateModified\":\"2023-01-26T14:40:35+00:00\",\"author\":{\"@id\":\"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240\"},\"description\":\"The Commission notice of 24th September 2018 indicates that the new EFSA\/ECHA guidance document on how to identify endocrine disruptors, adopted and\",\"breadcrumb\":{\"@id\":\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#primaryimage\",\"url\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/06\/test-tubes-904546_1920.jpg\",\"contentUrl\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/06\/test-tubes-904546_1920.jpg\",\"width\":1920,\"height\":1441},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/lynxee.consulting\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUROPE &#8211; COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lynxee.consulting\/#website\",\"url\":\"https:\/\/lynxee.consulting\/\",\"name\":\"Lynxee consulting\",\"description\":\"Innovative support for regulatory issues\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lynxee.consulting\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240\",\"name\":\"Adrien Margerit\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lynxee.consulting\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg\",\"contentUrl\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg\",\"caption\":\"Adrien Margerit\"},\"url\":\"https:\/\/lynxee.consulting\/en\/author\/adrien-margerit\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUROPE - COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors - Lynxee consulting","description":"The Commission notice of 24th September 2018 indicates that the new EFSA\/ECHA guidance document on how to identify endocrine disruptors, adopted and","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/","og_locale":"en_US","og_type":"article","og_title":"EUROPE - COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors - Lynxee consulting","og_description":"The Commission notice of 24th September 2018 indicates that the new EFSA\/ECHA guidance document on how to identify endocrine disruptors, adopted and","og_url":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/","og_site_name":"Lynxee consulting","article_published_time":"2018-09-30T14:55:07+00:00","article_modified_time":"2023-01-26T14:40:35+00:00","og_image":[{"width":1920,"height":1441,"url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/06\/test-tubes-904546_1920.jpg","type":"image\/jpeg"}],"author":"Adrien Margerit","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adrien Margerit","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/","url":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/","name":"EUROPE - COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors - Lynxee consulting","isPartOf":{"@id":"https:\/\/lynxee.consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#primaryimage"},"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/06\/test-tubes-904546_1920.jpg","datePublished":"2018-09-30T14:55:07+00:00","dateModified":"2023-01-26T14:40:35+00:00","author":{"@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240"},"description":"The Commission notice of 24th September 2018 indicates that the new EFSA\/ECHA guidance document on how to identify endocrine disruptors, adopted and","breadcrumb":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#primaryimage","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/06\/test-tubes-904546_1920.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/06\/test-tubes-904546_1920.jpg","width":1920,"height":1441},{"@type":"BreadcrumbList","@id":"https:\/\/lynxee.consulting\/en\/europe-com-availability-and-applicability-of-the-efsaecha-guidance-on-identifying-endocrine-disruptors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lynxee.consulting\/en\/"},{"@type":"ListItem","position":2,"name":"EUROPE &#8211; COM: Availability and applicability of the EFSA\/ECHA guidance on identifying endocrine disruptors"}]},{"@type":"WebSite","@id":"https:\/\/lynxee.consulting\/#website","url":"https:\/\/lynxee.consulting\/","name":"Lynxee consulting","description":"Innovative support for regulatory issues","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lynxee.consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240","name":"Adrien Margerit","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/image\/","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg","caption":"Adrien Margerit"},"url":"https:\/\/lynxee.consulting\/en\/author\/adrien-margerit\/"}]}},"_links":{"self":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/comments?post=2924"}],"version-history":[{"count":9,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2924\/revisions"}],"predecessor-version":[{"id":6283,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2924\/revisions\/6283"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media\/2241"}],"wp:attachment":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media?parent=2924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/categories?post=2924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/tags?post=2924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}